Patients with IDH-mutant glioma have better clinical outcomes compared with patients suffering from IDH-wildtype glioma [5,6], suggesting that there are unique physiological characteristics of IDH-mutant gliomas that may make them particularly vulnerable to specific therapies. Here, IDH1 is linked to central nervous system cancer.